Ascione A, et al. - In the sub-group of genotype-1 (GT1) patients older than 65 years, researchers examined safety and efficacy of treatment based on ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin (RBV). They collected data extracted from the ABACUS compassionate-use nationwide Italian programme, in patients with cirrhosis due to hepatitis C virus (HCV) GT1 or 4 and at high risk of decompensation. Findings suggested the safety and efficacy of ombitasvir, paritaprevir, ritonavir + dasabuvir + RBV in real-life use in patients with compensated cirrhosis, HCV-GT1 infection, and age over 65.